A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies.

ABSTRACT:

Objectives

Patients with hematological malignancies are likely to develop hypogammaglobulinemia. Immunoglobulin (Ig) is commonly given to prevent infections, but its overall costs and cost-effectiveness are unknown.

Methods

A systematic review was conducted following the PRISMA guidelines to assess the evidence on the costs and cost-effectiveness of Ig, administered intravenously (IVIg) or subcutaneously (SCIg), in adults with hematological malignancies.

Results

Six studies met the inclusion criteria, and only two economic evaluations were identified; one cost-utility analysis (CUA) of IVIg versus no Ig, and another comparing IVIg with SCIg. The quality of the evidence was low. Compared to no treatment, Ig reduced hospitalization rates. One study reported no significa

SUBMITTER: Carrillo de Albornoz S 

PROVIDER: S-EPMC11569901 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature